Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Endocytosis acts as transport pathway in wood.

Słupianek A, Kasprowicz-Maluśki A, Myśkow E, Turzańska M, Sokołowska K.

New Phytol. 2019 Jun;222(4):1846-1861. doi: 10.1111/nph.15637. Epub 2019 Jan 14.

PMID:
30548617
2.

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T.

J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8.

3.

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.

Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T.

Blood. 2013 Aug 15;122(7):1293-304. doi: 10.1182/blood-2013-05-501072. Epub 2013 Jul 8.

4.

BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.

Slupianek A, Falinski R, Znojek P, Stoklosa T, Flis S, Doneddu V, Pytel D, Synowiec E, Blasiak J, Bellacosa A, Skorski T.

Leukemia. 2013 Mar;27(3):629-34. doi: 10.1038/leu.2012.294. Epub 2012 Oct 9.

5.

Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.

Slupianek A, Dasgupta Y, Ren SY, Gurdek E, Donlin M, Nieborowska-Skorska M, Fleury F, Skorski T.

Blood. 2011 Jul 28;118(4):1062-8. doi: 10.1182/blood-2010-09-307256. Epub 2011 Jun 7.

6.

BCR/ABL stimulates WRN to promote survival and genomic instability.

Slupianek A, Poplawski T, Jozwiakowski SK, Cramer K, Pytel D, Stoczynska E, Nowicki MO, Blasiak J, Skorski T.

Cancer Res. 2011 Feb 1;71(3):842-51. doi: 10.1158/0008-5472.CAN-10-1066. Epub 2010 Dec 1.

7.

The chromatin remodeling factor SRCAP modulates expression of prostate specific antigen and cellular proliferation in prostate cancer cells.

Slupianek A, Yerrum S, Safadi FF, Monroy MA.

J Cell Physiol. 2010 Aug;224(2):369-75. doi: 10.1002/jcp.22132.

PMID:
20432434
8.

BCR/ABL kinase interacts with and phosphorylates the RAD51 paralog, RAD51B.

Slupianek A, Jozwiakowski SK, Gurdek E, Skorski T.

Leukemia. 2009 Dec;23(12):2308-10. doi: 10.1038/leu.2009.164. Epub 2009 Aug 6. No abstract available.

PMID:
19657362
9.

BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair.

Cramer K, Nieborowska-Skorska M, Koptyra M, Slupianek A, Penserga ET, Eaves CJ, Aulitzky W, Skorski T.

Cancer Res. 2008 Sep 1;68(17):6884-8. doi: 10.1158/0008-5472.CAN-08-1101.

10.

BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations.

Stoklosa T, Poplawski T, Koptyra M, Nieborowska-Skorska M, Basak G, Slupianek A, Rayevskaya M, Seferynska I, Herrera L, Blasiak J, Skorski T.

Cancer Res. 2008 Apr 15;68(8):2576-80. doi: 10.1158/0008-5472.CAN-07-6858.

11.

BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress.

Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T.

Leukemia. 2008 Oct;22(10):1969-72. doi: 10.1038/leu.2008.78. Epub 2008 Apr 10. No abstract available.

12.

[Uracil-DNA glycosylases].

Pytel D, Słupianek A, Ksiazek D, Skórski T, Błasiak J.

Postepy Biochem. 2008;54(4):362-70. Review. Polish.

PMID:
19248582
13.

[The role of oncogenic tyrosine kinases in the cellular response to anticancer therapy].

Słupianek A, Pytel D, Majsterek I.

Postepy Hig Med Dosw (Online). 2007 Dec 14;61:819-27. Polish.

14.

Brain tumor formation in tuberous sclerosis depends on Erk activation.

Jozwiak J, Grajkowska W, Kotulska K, Jozwiak S, Zalewski W, Zajaczkowska A, Roszkowski M, Slupianek A, Wlodarski P.

Neuromolecular Med. 2007;9(2):117-27.

PMID:
17627032
15.

Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells.

Rink L, Slupianek A, Stoklosa T, Nieborowska-Skorska M, Urbanska K, Seferynska I, Reiss K, Skorski T.

Blood. 2007 Jul 15;110(2):651-60. Epub 2007 Apr 12.

16.

ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks.

Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A, Koptyra M, Seferynska I, Krszyna K, Blasiak J, Skorski T.

Cell Cycle. 2006 May;5(9):994-1000. Epub 2006 May 1.

PMID:
16687921
17.

Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.

Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J.

Mutat Res. 2006 Jan 31;603(1):74-82. Epub 2006 Jan 4.

PMID:
16388976
18.

BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells.

Slupianek A, Nowicki MO, Koptyra M, Skorski T.

DNA Repair (Amst). 2006 Feb 3;5(2):243-50. Epub 2005 Nov 16.

20.

BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin.

Slupianek A, Gurdek E, Koptyra M, Nowicki MO, Siddiqui KM, Groden J, Skorski T.

Oncogene. 2005 Jun 2;24(24):3914-22.

PMID:
15750625
21.

NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner.

Slupianek A, Skorski T.

Exp Hematol. 2004 Dec;32(12):1265-71.

PMID:
15588951
22.

BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance.

Stoklosa T, Slupianek A, Datta M, Nieborowska-Skorska M, Nowicki MO, Koptyra M, Skorski T.

Cell Cycle. 2004 Nov;3(11):1463-72. Epub 2004 Nov 10.

PMID:
15492510
23.

BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks.

Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, Nieborowska-Skorska M, Blasiak J, Skorski T.

Blood. 2004 Dec 1;104(12):3746-53. Epub 2004 Aug 10.

PMID:
15304390
24.

ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance?

Majsterek I, Slupianek A, Hoser G, Skórski T, Blasiak J.

Biochimie. 2004 Jan;86(1):53-65.

PMID:
14987801
25.

TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin.

Majsterek I, Slupianek A, Blasiak J.

Anticancer Drugs. 2003 Sep;14(8):625-31.

PMID:
14501384
26.

Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?

Hoser G, Majsterek I, Romana DL, Slupianek A, Blasiak J, Skorski T.

Leuk Res. 2003 Mar;27(3):267-73.

PMID:
12537980
27.

The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE, Skorski T.

EMBO J. 2002 Nov 1;21(21):5766-74.

28.

Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.

Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T.

Oncogene. 2002 Aug 29;21(38):5868-76.

29.

Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.

Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, Skorski T.

Mol Cell Biol. 2002 Jun;22(12):4189-201.

30.

BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance.

Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, Pierce AJ, Fishel R, Skorski T.

Mol Cell. 2001 Oct;8(4):795-806.

31.

Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.

Nieborowska-Skorska M, Slupianek A, Xue L, Zhang Q, Raghunath PN, Hoser G, Wasik MA, Morris SW, Skorski T.

Cancer Res. 2001 Sep 1;61(17):6517-23.

32.

Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1.

Wang Q, Zhang H, Guerrette S, Chen J, Mazurek A, Wilson T, Slupianek A, Skorski T, Fishel R, Greene MI.

Oncogene. 2001 Aug 2;20(34):4640-9.

33.

Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.

Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA, Skorski T.

Cancer Res. 2001 Mar 1;61(5):2194-9.

34.

Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.

Nieborowska-Skorska M, Slupianek A, Skorski T.

Oncogene. 2000 Aug 24;19(36):4117-24.

35.

Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt.

Majewski M, Nieborowska-Skorska M, Salomoni P, Slupianek A, Reiss K, Trotta R, Calabretta B, Skorski T.

Cancer Res. 1999 Jun 15;59(12):2815-9.

36.

Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.

Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T.

J Exp Med. 1999 Apr 19;189(8):1229-42.

37.

Development of double copy dicistronic retroviral vectors for transfer and expression of glycosyltransferase genes.

Izycki D, Wiznerowicz M, Laciak M, Słupianek A, Mackiewicz A.

Adv Exp Med Biol. 1998;435:245-50. No abstract available.

PMID:
9498082
38.

Acute phase proteins and interleukin-6 serum levels in patients with chronic arterial occlusion.

Majewski W, Staniszewski R, Slupianek A, Gorny A, Mackiewicz A.

Ann N Y Acad Sci. 1995 Jul 21;762:493-5. No abstract available.

PMID:
7668569
39.

Interleukin-6-type cytokines affect glycosylation of acute phase proteins in vitro.

Gryska K, Slupianek A, Laciak M, Baumann H, Mackiewicz A.

Ann N Y Acad Sci. 1995 Jul 21;762:413-5. No abstract available.

PMID:
7545373
40.

Inflammatory cytokines controlling branching of N-heteroglycans of acute phase protein.

Gryska K, Słupianek A, Laciak M, Górny A, Mackiewicz K, Baumann H, Mackiewicz A.

Adv Exp Med Biol. 1995;376:239-45. No abstract available.

PMID:
8597254

Supplemental Content

Loading ...
Support Center